TG Therapeutics Class Action Lawsuit TGTX | Deadline September 16, 2022

TG Therapeutics Class Action Lawsuit (TGTX Lawsuit)

The Gross Law Firm notifies investors that a class action (TG Therapeutics Class Action Lawsuit) has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of TG Therapeutics, Inc. (TGTX) who purchased shares between January 15, 2020 and May 31, 2022.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:

(i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company’s therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until September 16, 2022 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

TGTX Class Action Lawsuit,
TGTX Class Action,
TGTX Lawsuit,
TGTX stock

SUBMIT FORM

TG Therapeutics, Inc. Class Action Lawsuit
TG Therapeutics, Inc. Lawsuit
TGTX Class Action Lawsuit
TGTX Lawsuit
TG Therapeutics, Inc. (TGTX) Class Action Lawsuit